NITYR® (nitisinone) Tablets are indicated for the treatment of patients with Hereditary Tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.
HT-1 is an ultra-rare genetic metabolic disease that can cause hepatic, renal and neurological complications. In most cases, if left untreated, the disease is fatal.
Cycle’s NITYR® (nitisinone) Tablets are approved in the US, Europe, Canada, Australia, New Zealand, Egypt, Chile, Saudi Arabia, Morocco and Israel and are also being prescribed in many regions around the world such as Latin America, Middle East, North Africa, South Africa, and South-East Asia.
NITYR® was developed after four years of research and development to find an alternative formulation to Orfadin* (nitisinone) capsules.
NITYR® is room temperature stable, comes as a small tablet (baby aspirin sized) and has a long (three (3) years) shelf life.
NITYR® Tablets are manufactured in Switzerland and the UK.
NITYR® is a patented pharmaceutical product with patents granted in the US 10328029 and EU EP3089740, and patents pending in other territories.
NITYR® is a registered trademark of Cycle Pharmaceuticals Limited in the United States.
NITYR® (nitisinone) Tablets is approved in the USA, Australia, New Zealand, the Kingdom of Saudi Arabia, the Kingdom of Morocco and Israel in 2, 5 and 10 mg strengths and in the EU, Egypt and Chile in 10 mg strength. Cycle Pharmaceuticals’ nitisinone products are also approved under a different name, NITISINONE TABLETS, in Canada in 2, 5, and 10 mg strengths. Registration conditions differ internationally.
*Orfadin is a registered trademark of Swedish Orphan Biovitrum International AB (publ).